Attending this event?
Back To Schedule
Tuesday, June 21 • 3:30pm - 4:00pm
#261 CH: How Drug Development Will Change Post-COVID

Sign up or log in to save this to your schedule, view media, leave feedback and see who's attending!

Component Type: Workshop
Level: Intermediate

The COVID-19 pandemic forced everyone to think and work differently. The good news is that many changes, independent of COVID, should become new standards for the way drug development is planned and executed. This Content Hub will discuss some of the areas that will become future paradigms for drug development. New ‘normal’ trends include: • Study Design • Decentralized Trial Solutions • Patient Centricity • Risk Management • Remote Monitoring • Trial Timelines Examples under each of these trends will be discuss.

Learning Objectives

Describe how COVID-19 changed existing drug development practices; Identify areas of change within your environment; Apply these changes as new standards for drug development.


Mark Kryah, PMP


Teresa Lamantia, MSN, RN

avatar for Mark Kryah

Mark Kryah

Executive Director/Program Team Leader, United States
Mark Kryah is an Executive Director at Ultragenyx Pharmaceutical, leading rare disease development programs. He has been leading global development projects for 20+ years, with extensive international and partnership experience. Mark has been involved with DIA for over 15 years, contributing... Read More →
avatar for Teresa Lamantia

Teresa Lamantia

Senior Vice President, Operational Transformation & Performance, IQVIA, United States
Teresa Lamantia is Sr. Vice President, Operational Transformation and Performance at IQVIA, the world’s largest CRO and healthcare data science company. In this role she oversees the metrics and reporting team as well as the lifecycle transition management team for research and... Read More →

Tuesday June 21, 2022 3:30pm - 4:00pm CDT
Room 470 A McCormick Place 2301 South Indiana Avenue Gate 40 Chicago, IL 60616